Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL023 vs Evenity Biosimilarity Study in Healthy Chinese Adults
NCT07384104Phase 1Enrolling by invitation
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of romosozumab in osteoporosis (2 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 85 days and Area Under the Concentration-Time Curve from Time Zero to Infinity at 85 days. Started Oct 2025; status: enrolling by invitation.
02
Drugs
romosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT07384104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07384104.